The clinical importance of IgA aB2GPI has increased in the last few years [6,7] due to the utilization of kits useful to detect IgA aB2GPI [8] and the task force in the 13th International Congress on Antiphospholipid Antibodies (2010, Galveston, TX, USA) recommended testing for the IgA aB2GPI in cases negative for IgG and IgM and when APS is still suspected [9,10]. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.